EP1233766A1 - Use of synergistic combinations of a nk 1? receptor antagonist and a gaba analog in psychiatric disorders - Google Patents

Use of synergistic combinations of a nk 1? receptor antagonist and a gaba analog in psychiatric disorders

Info

Publication number
EP1233766A1
EP1233766A1 EP00979495A EP00979495A EP1233766A1 EP 1233766 A1 EP1233766 A1 EP 1233766A1 EP 00979495 A EP00979495 A EP 00979495A EP 00979495 A EP00979495 A EP 00979495A EP 1233766 A1 EP1233766 A1 EP 1233766A1
Authority
EP
European Patent Office
Prior art keywords
receptor antagonist
gaba analog
methyl
disorder
psychiatric disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00979495A
Other languages
German (de)
French (fr)
Inventor
John Hughes
Lakhbir Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of EP1233766A1 publication Critical patent/EP1233766A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a method for preventing and for treating psychiatric disorders through the use of effective amounts of synergistic NKi receptor antagonist/GABA analog combinations.
  • Neurokinin 1 (NKj) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins.
  • a selective NK] receptor antagonist [2-(lH-indol-3-yl)-l-methyl-l-(l-phenyl- ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester, has been shown in the rat to block the maintenance of streptozocin-induced static allodynia (Field et al., (1998) J. Pharmacol. Exp. Ther. 285: 1226-1232).
  • Gabapentin (l-(aminomethyl)cyclohexane acetic acid) is an antiepileptic drug.
  • this invention provides a method for preventing or treating a psychiatric disorder comprising administering to a subject in need of treatment an amount of a synergistic combination of a NK] receptor antagonist and a GABA analog.
  • the psychiatric disorder treated is anxiety, panic attack, generalized anxiety disorder, social phobia or depression.
  • the invention also concerns the use of a composition comprising synergistic effective amounts of a NK] receptor antagonist and a GABA analog, or pharmaceutically acceptable salts thereof, for the preparation of a medicament useful for preventing or treating a psychiatric disorder.
  • FIGURE 1 Dose response 30 min post drug for [2-( l -indol-3-yl)-l -methyl- 1-
  • a NK] receptor antagonist is used in combination with a GABA analog to treat a psychiatric disorder in patients in need of such treatment.
  • the compounds can be employed individually or can be combined in a single formulation, for example as a tablet, capsule, syrup, solution, as well as controlled release formulations.
  • the NK] receptor antagonist and GABA analog are formulated individually and administered in the same manner that each is normally used clinically, but with reduced amounts of each.
  • the NK] receptor antagonists, such as capsaicin can be used herein.
  • Specific NK] receptor antagonists that can be used herein are disclosed in U.S. Patent Nos.
  • NK] receptor antagonists that can be used herein are disclosed in U.S. Patent No.
  • a more preferred NK ] receptor antagonist is [2-(lH-indol-3-yl)-l - methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl] -carbamic acid benzofuran-2-ylmethyl ester.
  • GABA structural analogs can be used within the context of the invention.
  • Specific GABA analogs that can be used herein are disclosed in U.S. Patent Nos. 4,024,175 and 5,563,175, which are incorporated herein by reference.
  • Preferred GABA analogs include a cyclic amino acid compound of Formula I: wherein R 1 is hydrogen or lower alkyl and n is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof.
  • An especially preferred embodiment utilizes a GABA analog of Formula I where R 1 is hydrogen and n is 5, which compound is generically known as gabapentin.
  • Other preferred GABA analogs have Formula I wherein the cyclic ring is substituted, for example with alkyl such as methyl or ethyl.
  • Typical of such compounds include (l-aminomethyl-3- methylcyclohexyl) acetic acid, (l-aminomethyl-3-methylcyclopentyl) acetic acid and (l-aminomethyl-3-4-dimethylcyclopentyl) acetic acid.
  • the method for preventing and treating a psychiatric disorder of the invention utilizes as a GABA analog a compound of Formula II:
  • R 1 is straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl of from 3 to 6 carbon atoms;
  • R2 is hydrogen or methyl
  • R3 is hydrogen, methyl, or carboxyl.
  • Diastereoisomers and enantiomers of compounds of Formula II can be utilized in the invention.
  • An especially preferred method of the invention employs as GABA analog a compound of Formula II where R 2 and R ⁇ are both hydrogen, and R 1 is -(CH 2 )o-2-'C 4 Ho, as an (R), (S), or
  • (R,S) isomer A more preferred embodiment of the invention employs, as GABA analog, 3-aminomethyl-5-methyl-hexanoic acid, and especially (S)-3-amino- methyl-5-methyl-hexanoic acid, known generically as pregabalin.
  • Another preferred compound of Formula II is 3-(l-aminoethyl)-5-methyl-heptanoic acid.
  • the dosage of each agent will vary depending upon the severity of the disease or disorder, the frequency of administration, the particular agents, and combinations utilized, and other factors routinely considered by an attending medical practitioner.
  • the NK ] receptor antagonist is normally administered at a daily dose of from about 0.25 mg to about 500 mg, typically about 3 mg to about
  • the GABA analog is normally administered at doses from about 5 mg to about 2500 mg per day, and more typically from about 50 mg to about 1500 mg per day.
  • a preferred GABA analog is gabapentin, and it is employed at doses from about 100 mg to about 1000 mg per day.
  • a NK] receptor antagonist utilized in the present invention includes solvates, hydrates, pharmaceutically acceptable salts, and polymorphs (different crystalline lattice descriptors) of the NK ] receptor antagonist.
  • a GABA analog utilized in the present invention includes solvates, hydrates, pharmaceutically acceptable salts, and polymorphs (different crystalline lattice descriptors) of the GABA analog.
  • the pharmaceutically acceptable salts include acetate, benzene- sulfonate, benzoate, bitartrate, calcium acetate, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogencarbonate, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate
  • psychiatric disorder is intended to include anxiety, panic attacks, generalized anxiety disorder, social phobia and depression. All that is required to practice the method of preventing and treating a psychiatric disorder according to the present invention is to administer a synergistic NKj-GABA analog combination in an amount that is effective to prevent or treat the disorder, i.e. to control the psychiatric disorder.
  • a pharmaceutical composition for the treatment or prevention of a psychiatric disorder comprising the synergistic NKi antagonist - GABA analog combination.
  • Formulating the active components of the combination in dosage unit form with at least one pharmaceutically acceptable carrier or excipient produces pharmaceutical formulations of the composition according to the present invention.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. They preferably contain 5% to about 70% of the active components of the combination.
  • the active com- ponents are admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) ab
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose as well as high molecular weight polyethyleneglycols, and the like.
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They can also be of such composition that they release the active components in a certain part of the intestinal tract in a delayed manner.
  • coatings and shells such as enteric coatings and others well known in the art. They can also be of such composition that they release the active components in a certain part of the intestinal tract in a delayed manner.
  • embedding compositions that can be used are polymeric substances and waxes.
  • the active components of the combination can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, and the like.
  • Suspensions in addition to the active components, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • suspending agents as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • compositions for rectal administrations are preferably suppositories which can be prepared by mixing the active components of the combination of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature, and therefore melt in the rectum and release the active components of the combination.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature, and therefore melt in the rectum and release the active components of the combination.
  • compositions suitable for parenteral injection may comprise physio- logically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions of the active components of the combination, and also sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable liquid carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), and suitable mixtures thereof.
  • compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
  • Various antibacterial and antifungal agents for example, parabens, chlorobutanol, phenol, sorbic acid, and the like can ensure prevention of the action of microorganisms. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is divided into unit doses containing appropriate quantities of the active components of the combination.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • Some examples of dosage unit forms are tablets, capsules, pills, powders, suppositories, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses.
  • the percentage of the active components in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a concentration of at least 10 % in a solid composition and at least 2 % in a primary liquid composition.
  • the most satisfactory compositions are those in which a much higher proportion of the active components is present, for example, from 10 % to 90 % by weight.
  • a useful oral dosage is between 20 and 800 mg , expressed as the mass of the GABA analog, and a useful intravenous dose is between 5 and 50 mg.
  • the dosage is within the dosing range used in treatment of a psychiatric disorder, or as would be dictated by the needs of the patient as described by the physician.
  • the invention provides compositions of a NK ] receptor antagonist and a
  • NK] receptor antagonist can be combined with any NK] receptor antagonist
  • GABA analog according to this invention.
  • Preferred GABA analogs to be employed are the compounds of Formula I and II, especially gabapentin and pregabalin.
  • Preferred NK] receptor antagonists to be employed in the compositions include (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)- amine, and [2-(lH-indol-3-yl)-l-methyl-l-(l-phenyl-ethylcarbamoyl)-ethyl]-carb- amic acid benzofuran-2-ylmethyl ester.
  • the composition contains about 1 to about 1000 parts by weight of GABA analog, and about 1000 to about 1 part by weight NK] receptor antagonist.
  • a typical composition of gabapentin and [2-(lH-indol-3-yl)-l- methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester contains about 400 mg of gabapentin and about 20 mg of the NK] receptor antagonist. Such combination is administered to an adult patient about twice a day to achieve a synergistic control of a psychiatric disorder.
  • the compositions may contain common pharmaceutical excipients such as those described above.
  • the advantages of using the combination of a NK ] receptor antagonist and a GABA analog of the instant invention include the selective activity of the combination on a psychiatric disorder, the relatively nontoxic nature of the combination, the ease of preparation, the fact that the combination is well tolerated, and the ease of i.v. and, in particular, oral administration of the combination.
  • the ability of synergistic NKi -receptor antagonist-GABA analog combinations to prevent or treat a psychiatric disorder has been established in several animal models.
  • EXAMPLE 1 Synergistic interaction between a NK ] -receptor antagonist and a GABA analog in isolation-induced vocalizations of guinea-pig pups
  • Distress vocalizations of guinea-pig pups (2-14 days old) are quantified in a 5-min isolation period, after which they are reunited with their mothers and littermates.
  • the test cage consists of a sound-attenuating box with a white interior and white illumination.
  • the vocalizations are recorded by means of a microphone and a digital audio tape (DAT) recorder.
  • DAT digital audio tape
  • Pups are first selected using the criterion of emitting a minimum of 500 vocalizations after three pre-tests on three consecutive days.
  • pups are submitted to a pre-treatment (baseline) measurement. Each pup then receives oral administration of test compounds and is returned to the home cage for 30 min before maternal separation.
  • Different ratios of combinations of doses are administered to groups of animals
  • the benzofuranyl-methyl ester, gabapentin, lactose, and corn starch (for mix) are blended to uniformity.
  • the corn starch (for paste) is suspended in 400 mL of water and heated with stirring to form a paste.
  • the paste is used to granulate the mixed powders.
  • the wet granules are passed through a No. 8 hand screen and dried.
  • the dry granules are lubricated with the 1 % magnesium stearate and pressed into a tablet.
  • Such tablets can be administered to a human from one to four times a day for treatment of a psychiatric disorder.
  • the sorbitol solution is added to 40 mL of distilled water, and pregabalin and the benzofuranylmethyl ester are dissolved therein.
  • the saccharin, sodium benzoate, flavor, and dye are added and dissolved.
  • the volume is adjusted to 100 mL with distilled water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods of treatment using synergistic combinations of a NK1 receptor antagonist and a GABA analog, and pharmaceutical compositions and products containing the NK1 receptor antagonist and GABA analog. The present invention provides the use of a NK1 receptor antagonist and a GABA analog for the manufacture of a medicament for the treatment or prevention of psychiatric disorders.

Description

USE OF SYNERGISTIC COMBINATIONS OF
A NKi RECEPTOR ANTAGONIST AND A GABA ANALOG IN
PSYCHIATRIC DISORDERS
FIELD OF THE INVENTION
This invention relates to a method for preventing and for treating psychiatric disorders through the use of effective amounts of synergistic NKi receptor antagonist/GABA analog combinations.
BACKGROUND OF THE INVENTION
Neurokinin 1 (NKj) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins.
A selective NK] receptor antagonist, [2-(lH-indol-3-yl)-l-methyl-l-(l-phenyl- ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester, has been shown in the rat to block the maintenance of streptozocin-induced static allodynia (Field et al., (1998) J. Pharmacol. Exp. Ther. 285: 1226-1232).
Gabapentin (l-(aminomethyl)cyclohexane acetic acid) is an antiepileptic drug.
SUMMARY OF THE INVENTION
It has now been discovered that combination therapy with a NK] receptor antagonist and a GABA analog results in dramatic improvement in psychiatric disorders control. When administered together, the NK] receptor antagonist and the GABA analog can interact in a synergistic manner to control a psychiatric disorder. This unexpected synergy allows a reduction in the dose required of each compound, leading to a reduction in the side effects, and enhancement of the clinical utility of the compounds.
Accordingly, this invention provides a method for preventing or treating a psychiatric disorder comprising administering to a subject in need of treatment an amount of a synergistic combination of a NK] receptor antagonist and a GABA analog.
Preferably, the psychiatric disorder treated is anxiety, panic attack, generalized anxiety disorder, social phobia or depression.
The invention also concerns the use of a composition comprising synergistic effective amounts of a NK] receptor antagonist and a GABA analog, or pharmaceutically acceptable salts thereof, for the preparation of a medicament useful for preventing or treating a psychiatric disorder.
BRIEF DESCRIPTION OF THE DRAWING
FIGURE 1. Dose response 30 min post drug for [2-( l -indol-3-yl)-l -methyl- 1-
(l-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester (CI-1021) in the isolation-induced vocalization model of anxiety in the guinea pig pup. Results are shown as mean % reduction ± SEM in the number of calls vs. baseline measurements taken before the treatment. *: P<0.05 vs vehicle group; #: PO.05 vs their own vehicles (not included in the graph for clarity); Kruskall-Wallis test followed by Mann- Whitney test.
DETAILED DESCRIPTION OF THE INVENTION
According to this invention, a NK] receptor antagonist is used in combination with a GABA analog to treat a psychiatric disorder in patients in need of such treatment. The compounds can be employed individually or can be combined in a single formulation, for example as a tablet, capsule, syrup, solution, as well as controlled release formulations. In a preferred embodiment, the NK] receptor antagonist and GABA analog are formulated individually and administered in the same manner that each is normally used clinically, but with reduced amounts of each. The NK] receptor antagonists, such as capsaicin can be used herein. Specific NK] receptor antagonists that can be used herein are disclosed in U.S. Patent Nos. 3,862,114, 3,912,711, 4,472,305, 4,481,139, 4,680,283, 4,839,465, 5,102,667, 5,162,339, 5,164,372, 5,166,136, 5,232,929, 5,242,944, 5,300,648, 5,310,743,
5,338,845, 5,340,822, 5,378,803, 5,410,019, 5,411,971, 5,420,297, 5,422,354, 5,446,052, 5,451,586, 5,525,712, 5,527,811, 5,536,737, 5,541,195, 5,594,022, 5,561,113, 5,576,317, 5,604,247, 5,624,950, and 5,635,510; World Patent Application Nos. WO 90/05525, WO 91/09844, WO 91/12266, WO 92/06079, WO 92/12151, WO 92/15585, WO 92/20661, WO 92/20676, WO 92/21677,
WO 92/22569, WO 93/00330, WO 93/00331, WO 93/01159, WO 93/01160, WO 93/01165, WO 93/01169, WO 93/01170, WO 93/06099, WO 93/10073, WO 93/14084, WO 93/19064, WO 93/21155, WO 94/04496, WO 94/08997, WO 94/29309, WO 95/11895, WO 95/14017; WO 97/19942, WO 97/24356; WO 97/38692, WO 98/02158, and WO 98/07694; European Patent Application
Nos. 284942, 327009, 333174, 336230, 360390, 394989, 428434, 429366, 443132, 446706, 484719, 499313, 512901, 512902, 514273, 514275, 515240, 520555, 522808, 528495, 532456, and 591040. Preferred NK] receptor antagonists that can be used herein are disclosed in U.S. Patent No. 5,594,022; among these, a more preferred NK] receptor antagonist is [2-(lH-indol-3-yl)-l - methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl] -carbamic acid benzofuran-2-ylmethyl ester.
Any GABA structural analogs can be used within the context of the invention. Specific GABA analogs that can be used herein are disclosed in U.S. Patent Nos. 4,024,175 and 5,563,175, which are incorporated herein by reference.
Preferred GABA analogs include a cyclic amino acid compound of Formula I: wherein R1 is hydrogen or lower alkyl and n is an integer of from 4 to 6, and the pharmaceutically acceptable salts thereof. An especially preferred embodiment utilizes a GABA analog of Formula I where R1 is hydrogen and n is 5, which compound is generically known as gabapentin. Other preferred GABA analogs have Formula I wherein the cyclic ring is substituted, for example with alkyl such as methyl or ethyl. Typical of such compounds include (l-aminomethyl-3- methylcyclohexyl) acetic acid, (l-aminomethyl-3-methylcyclopentyl) acetic acid and (l-aminomethyl-3-4-dimethylcyclopentyl) acetic acid. In another embodiment, the method for preventing and treating a psychiatric disorder of the invention utilizes as a GABA analog a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein
R1 is straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl of from 3 to 6 carbon atoms;
R2 is hydrogen or methyl; and
R3 is hydrogen, methyl, or carboxyl. Diastereoisomers and enantiomers of compounds of Formula II can be utilized in the invention. An especially preferred method of the invention employs as GABA analog a compound of Formula II where R2 and R^ are both hydrogen, and R1 is -(CH2)o-2-'C4Ho, as an (R), (S), or
(R,S) isomer. A more preferred embodiment of the invention employs, as GABA analog, 3-aminomethyl-5-methyl-hexanoic acid, and especially (S)-3-amino- methyl-5-methyl-hexanoic acid, known generically as pregabalin. Another preferred compound of Formula II is 3-(l-aminoethyl)-5-methyl-heptanoic acid. The dosage of each agent will vary depending upon the severity of the disease or disorder, the frequency of administration, the particular agents, and combinations utilized, and other factors routinely considered by an attending medical practitioner. The NK] receptor antagonist is normally administered at a daily dose of from about 0.25 mg to about 500 mg, typically about 3 mg to about
250 mg. The GABA analog is normally administered at doses from about 5 mg to about 2500 mg per day, and more typically from about 50 mg to about 1500 mg per day. A preferred GABA analog is gabapentin, and it is employed at doses from about 100 mg to about 1000 mg per day. A NK] receptor antagonist utilized in the present invention includes solvates, hydrates, pharmaceutically acceptable salts, and polymorphs (different crystalline lattice descriptors) of the NK] receptor antagonist.
A GABA analog utilized in the present invention includes solvates, hydrates, pharmaceutically acceptable salts, and polymorphs (different crystalline lattice descriptors) of the GABA analog.
Where it is appropriate to form a salt of the NK] receptor antagonist or of the GABA analog, the pharmaceutically acceptable salts include acetate, benzene- sulfonate, benzoate, bitartrate, calcium acetate, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogencarbonate, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate or hemi-succinate, sulfate or hemi-sulfate, tannate, tartrate or hemi-tartrate, theoclate, triethiodide, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, ammonium, tetramethyl ammonium, calcium, lithium, magnesium, potassium, sodium, and zinc. (See also "Pharmaceutical salts" by Berge S.M. et al. (1997) J. Pharm. Sci. 66: 1-19, which is incorporated herein by reference.) The terms "patient" and "subject" are intended to include a mammal, especially a human.
The term "psychiatric disorder" is intended to include anxiety, panic attacks, generalized anxiety disorder, social phobia and depression. All that is required to practice the method of preventing and treating a psychiatric disorder according to the present invention is to administer a synergistic NKj-GABA analog combination in an amount that is effective to prevent or treat the disorder, i.e. to control the psychiatric disorder.
In a further aspect of the present invention, there is provided a pharmaceutical composition for the treatment or prevention of a psychiatric disorder comprising the synergistic NKi antagonist - GABA analog combination.
Formulating the active components of the combination in dosage unit form with at least one pharmaceutically acceptable carrier or excipient produces pharmaceutical formulations of the composition according to the present invention. For preparing pharmaceutical formulations from the compounds used in this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. They preferably contain 5% to about 70% of the active components of the combination. In such solid dosage forms, the active com- ponents are admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose as well as high molecular weight polyethyleneglycols, and the like.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They can also be of such composition that they release the active components in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes.
The active components of the combination can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active components of the combination, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, and the like.
Suspensions, in addition to the active components, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the active components of the combination of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature, and therefore melt in the rectum and release the active components of the combination.
Compositions suitable for parenteral injection may comprise physio- logically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions of the active components of the combination, and also sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable liquid carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), and suitable mixtures thereof.
These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like can ensure prevention of the action of microorganisms. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like.
Preferably the pharmaceutical preparation is in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of the active components of the combination. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. Some examples of dosage unit forms are tablets, capsules, pills, powders, suppositories, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses. The percentage of the active components in the foregoing compositions can be varied within wide limits, but for practical purposes it is preferably present in a concentration of at least 10 % in a solid composition and at least 2 % in a primary liquid composition. The most satisfactory compositions are those in which a much higher proportion of the active components is present, for example, from 10 % to 90 % by weight.
Routes of administration of the active components of the combination or their respective salts are parenteral or, preferably, oral. For example, a useful oral dosage is between 20 and 800 mg , expressed as the mass of the GABA analog, and a useful intravenous dose is between 5 and 50 mg. The dosage is within the dosing range used in treatment of a psychiatric disorder, or as would be dictated by the needs of the patient as described by the physician. The invention provides compositions of a NK] receptor antagonist and a
GABA analog, and a method of treating a psychiatric disorder comprising administering to a patient in need of treatment an amount of a NK] receptor antagonist and an effective amount of a GABA analogue effective in this psychiatric disorder. Any NK] receptor antagonist can be combined with any
GABA analog according to this invention. Preferred GABA analogs to be employed are the compounds of Formula I and II, especially gabapentin and pregabalin. Preferred NK] receptor antagonists to be employed in the compositions include (2-methoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)- amine, and [2-(lH-indol-3-yl)-l-methyl-l-(l-phenyl-ethylcarbamoyl)-ethyl]-carb- amic acid benzofuran-2-ylmethyl ester.
When the GABA analog and the NK] receptor antagonist are formulated together, the composition contains about 1 to about 1000 parts by weight of GABA analog, and about 1000 to about 1 part by weight NK] receptor antagonist. Preferred ranges for the ratio of the two active principles, expressed as parts by weight of the GABA analog relative to parts of the NKj receptor antagonist, are
50: 1 to 1 :1. A most preferred range for the ratio of the two active principles is
20:1. For example a typical composition of gabapentin and [2-(lH-indol-3-yl)-l- methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester contains about 400 mg of gabapentin and about 20 mg of the NK] receptor antagonist. Such combination is administered to an adult patient about twice a day to achieve a synergistic control of a psychiatric disorder. The compositions may contain common pharmaceutical excipients such as those described above.
The advantages of using the combination of a NK] receptor antagonist and a GABA analog of the instant invention include the selective activity of the combination on a psychiatric disorder, the relatively nontoxic nature of the combination, the ease of preparation, the fact that the combination is well tolerated, and the ease of i.v. and, in particular, oral administration of the combination. The ability of synergistic NKi -receptor antagonist-GABA analog combinations to prevent or treat a psychiatric disorder has been established in several animal models.
EXAMPLE 1 Synergistic interaction between a NK] -receptor antagonist and a GABA analog in isolation-induced vocalizations of guinea-pig pups
Methods;
Distress vocalizations of guinea-pig pups (2-14 days old) are quantified in a 5-min isolation period, after which they are reunited with their mothers and littermates. The test cage consists of a sound-attenuating box with a white interior and white illumination. The vocalizations are recorded by means of a microphone and a digital audio tape (DAT) recorder. Pups are first selected using the criterion of emitting a minimum of 500 vocalizations after three pre-tests on three consecutive days. On the day of the test, pups are submitted to a pre-treatment (baseline) measurement. Each pup then receives oral administration of test compounds and is returned to the home cage for 30 min before maternal separation. Different ratios of combinations of doses are administered to groups of animals
(n= 9-10 per group). A minimum of 3 total doses for each ratio of combination is examined. The difference in the number of calls emitted before and after treatment is counted using Spike2 software; percentage of reduction in the number of calls is analyzed using a Kruskall-Wallis test followed by Mann- Whitney test between vehicle and different treatments. For example, the oral administration of [2-(lH- indol-3-yl)- 1 -methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzo- furan-2-ylmethyl ester (0.01-10.0 mg/kg p.o., in Gelucire™ vehicle 30 min before the test) dose-dependently blocked vocalizations with a MED of 1.0 mg/kg (Figure 6). With different ratios of combinations of doses of a NK] receptor antagonist and a GABA analog, a synergistic interaction is considered when a significant shift to the left from the additive line is achieved. The following examples illustrate typical formulations provided by the invention.
EXAMPLE 2 Tablet Formulation
Ingredient Amount (mg)
[2-( 1 H-indol-3 -yl)- 1 -methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl]- 5 carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)]
Gabapentin 100
Lactose 95
Corn starch (for mix) 20
Corn starch (paste) 20
Magnesium stearate (1%) 10
Total 250
The benzofuranyl-methyl ester, gabapentin, lactose, and corn starch (for mix) are blended to uniformity. The corn starch (for paste) is suspended in 400 mL of water and heated with stirring to form a paste. The paste is used to granulate the mixed powders. The wet granules are passed through a No. 8 hand screen and dried. The dry granules are lubricated with the 1 % magnesium stearate and pressed into a tablet. Such tablets can be administered to a human from one to four times a day for treatment of a psychiatric disorder.
EXAMPLE 3
Preparation for Oral Solution
Ingredient Amount
[2-( 1 H-indol-3 -yl)- 1 -methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl]- 20 mg carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)]
Pregabalin 400 mg Sorbitol solution (70% N.F.) 40 mL
Sodium benzoate 20 mg
Saccharin 5 mg
Red dye 10 mg
Cherry flavor 20 mg
Distilled water q.s. 100 mL
The sorbitol solution is added to 40 mL of distilled water, and pregabalin and the benzofuranylmethyl ester are dissolved therein. The saccharin, sodium benzoate, flavor, and dye are added and dissolved. The volume is adjusted to 100 mL with distilled water.
EXAMPLE 4 Parenteral Solution
In a solution of 700 mL of propylene glycol and 200 mL of water for injection is added 0.5 g of [2-(lH-indol-3-yl)-l-methyl-l-(l-phenyl-ethylcarbamoyl)-ethyl]- carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and 10 g of pregabalin. The pH is adjusted to 6.5, and the volume is made up to 1000 mL with water for injection. The formulation is sterilized, filled into 5.0 mL ampoules each containing 2.0 mL, and sealed under nitrogen.

Claims

CLAIMSWhat is claimed is:
1. A method for preventing or for treating a psychiatric disorder comprising administering to a patient in need of treatment an effective amount of a synergistic combination of a NK] receptor antagonist and a GABA analog.
2. A method of Claim 1 wherein the ratio of the GABA analog relative to the NK] receptor antagonist is from 50:1 to 1 :1 expressed as parts by weight.
3. A method of Claim 1 wherein the ratio of the GABA analog relative to the
NK] receptor antagonist is 20: 1 expressed as parts by weight.
4. A method according to Claim 1 wherein the NK] receptor antagonist is [2-
( 1 H-indol-3-yl)- 1 -methyl- 1 -( 1 -phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)].
5. A method according to Claim 1 wherein the GABA analog is gabapentin.
6. A method according to Claim 1 wherein the GABA analog is pregabalin.
7. A method according to Claim 1 employing [2-(lH-indol-3-yl)-l -methyl- 1- (l-phenyl-ethylcarbamoyl)-ethyl] -carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and gabapentin.
8. A method according to Claim 1 employing [2-(l H-indol-3 -yl)-l -methyl- 1-
(l-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2-ylmethyl ester [R-(R*,S*)] and pregabalin.
. A method according to any one of claims 1 to 8 wherein the disorder treated is selected from anxiety, panic attacks, generalized anxiety disorder, social phobia or depression.
10. The use of a composition comprising synergistic amounts of a NK] receptor antagonist and a GABA analog effective in a psychiatric disorder, or pharmaceutically acceptable salts thereof, for the preparation of a medicament useful for preventing or treating a psychiatric disorder.
11. Use according to claim 10 characterized in that a psychiatric disorder is selected from anxiety, panic attacks, generalized anxiety disorder, social phobia and depression.
EP00979495A 1999-10-07 2000-10-09 Use of synergistic combinations of a nk 1? receptor antagonist and a gaba analog in psychiatric disorders Withdrawn EP1233766A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
US158271P 1999-10-07
PCT/EP2000/010084 WO2001024791A1 (en) 1999-10-07 2000-10-09 Use of synergistic combinations of a nk1 receptor antagonist and a gaba analog in psychiatric disorders

Publications (1)

Publication Number Publication Date
EP1233766A1 true EP1233766A1 (en) 2002-08-28

Family

ID=22567369

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00966138A Expired - Lifetime EP1221950B1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
EP00979495A Withdrawn EP1233766A1 (en) 1999-10-07 2000-10-09 Use of synergistic combinations of a nk 1? receptor antagonist and a gaba analog in psychiatric disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP00966138A Expired - Lifetime EP1221950B1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Country Status (38)

Country Link
EP (2) EP1221950B1 (en)
JP (2) JP2003510356A (en)
KR (1) KR20020060192A (en)
CN (1) CN1387434A (en)
AP (1) AP2002002501A0 (en)
AR (1) AR029646A1 (en)
AT (1) ATE269072T1 (en)
AU (2) AU7663300A (en)
BG (1) BG106548A (en)
BR (1) BR0014598A (en)
CA (1) CA2385930A1 (en)
CO (1) CO5280195A1 (en)
CR (1) CR6614A (en)
CZ (1) CZ20021116A3 (en)
DE (1) DE60011650T2 (en)
DK (1) DK1221950T3 (en)
EA (1) EA004266B1 (en)
EE (1) EE200200185A (en)
ES (1) ES2220542T3 (en)
GT (1) GT200000166A (en)
HR (1) HRP20020286A2 (en)
HU (1) HUP0203466A3 (en)
IL (1) IL148965A0 (en)
IS (1) IS6318A (en)
MA (1) MA26826A1 (en)
MX (1) MXPA02003484A (en)
NO (1) NO20021625D0 (en)
NZ (1) NZ517949A (en)
OA (1) OA12063A (en)
PA (1) PA8504301A1 (en)
PE (1) PE20010708A1 (en)
PL (1) PL357498A1 (en)
PT (1) PT1221950E (en)
SK (1) SK4542002A3 (en)
TR (1) TR200200913T2 (en)
UY (1) UY26376A1 (en)
WO (2) WO2001024792A1 (en)
ZA (1) ZA200202675B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (en) 1996-07-24 2005-10-31 Warner Lambert Co Isobutylgabe and its derivatives useful in relieving pains
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1662231A (en) * 2002-04-24 2005-08-31 柏树生物科学公司 Prevention and treatment of functional somatic disorders, including stress-related disorders
CN1720025A (en) * 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 Gabapentin tablets and methods for their preparation
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (en) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilized pharmaceutical composition containing pregabalin
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
DK2621282T3 (en) * 2010-09-28 2020-05-04 Univ California GABA AGONISTS IN THE TREATMENT OF DISORDERS CONNECTED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXY OF TYPE IN DIABETES
DK3946260T3 (en) * 2019-03-26 2026-03-23 Orion Corp Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE69736390T2 (en) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon CNS PENETRATING NK-1 RECEPTOR ANTAGONISTS AS ANTIDEPRESSIVE AND / OR ANXIOLYTIC
JP2001504848A (en) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド Use of an NK-1 receptor antagonist for the treatment of severe anxiety disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0124791A1 *

Also Published As

Publication number Publication date
IL148965A0 (en) 2002-11-10
HUP0203466A2 (en) 2003-02-28
AR029646A1 (en) 2003-07-10
HRP20020286A2 (en) 2003-08-31
BR0014598A (en) 2002-06-11
WO2001024792A1 (en) 2001-04-12
DE60011650T2 (en) 2005-07-14
GT200000166A (en) 2002-03-30
MXPA02003484A (en) 2004-09-10
CA2385930A1 (en) 2001-04-12
HUP0203466A3 (en) 2005-03-29
PE20010708A1 (en) 2001-07-27
AP2002002501A0 (en) 2002-06-30
DK1221950T3 (en) 2004-09-20
OA12063A (en) 2006-05-03
CO5280195A1 (en) 2003-05-30
WO2001024792A9 (en) 2002-09-06
SK4542002A3 (en) 2003-09-11
EP1221950B1 (en) 2004-06-16
BG106548A (en) 2002-12-29
UY26376A1 (en) 2000-12-29
MA26826A1 (en) 2004-12-20
JP2003510355A (en) 2003-03-18
KR20020060192A (en) 2002-07-16
WO2001024791A1 (en) 2001-04-12
EP1221950A1 (en) 2002-07-17
CZ20021116A3 (en) 2003-05-14
NO20021625L (en) 2002-04-05
NO20021625D0 (en) 2002-04-05
PA8504301A1 (en) 2002-08-26
JP2003510356A (en) 2003-03-18
ATE269072T1 (en) 2004-07-15
NZ517949A (en) 2003-08-29
CN1387434A (en) 2002-12-25
CR6614A (en) 2003-12-04
PL357498A1 (en) 2004-07-26
AU7663300A (en) 2001-05-10
IS6318A (en) 2002-03-21
EA004266B1 (en) 2004-02-26
TR200200913T2 (en) 2002-09-23
DE60011650D1 (en) 2004-07-22
EA200200303A1 (en) 2002-08-29
EE200200185A (en) 2003-04-15
ZA200202675B (en) 2003-04-15
PT1221950E (en) 2004-08-31
AU1696201A (en) 2001-05-10
ES2220542T3 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
JP4925074B2 (en) A pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6306910B1 (en) Use of Gaba-analogues for treating insomnia
WO2000050027A1 (en) Gabapentin derivative for preventing and treating visceral pain
EP1233766A1 (en) Use of synergistic combinations of a nk 1? receptor antagonist and a gaba analog in psychiatric disorders
CA2414111A1 (en) Use of substituted indole compounds for increasing nitric oxide synthase activity
JPH08507774A (en) Use of granisetron for the treatment of postoperative nausea and vomiting
US6680343B1 (en) Treatment of renal colic with GABA analogs
US20060160887A1 (en) Medicinal composition
PT1562571E (en) Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
AU763615B2 (en) Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption
JP2002520300A (en) Pharmaceutical composition for treating herpes zoster comprising a GABA analog and an antiviral agent
CN1930123A (en) Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
US4363809A (en) Organic compounds
WO1999059635A1 (en) Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
US20040097573A1 (en) Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
KR20250044649A (en) Thyroid beta-agonist regimen for the treatment of X-ALD
AU2009333303A1 (en) Enema formulations
FR2605885A1 (en) DRUG ASSOCIATION BASED ON A CALCIUM INHIBITOR
US20050059741A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
CA2060312A1 (en) Antitussive preparation
ZA200007172B (en) The treatment of renal colic with GABA analogs.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020507;LT PAYMENT 20020507;LV PAYMENT 20020507;MK PAYMENT 20020507;RO PAYMENT 20020507;SI PAYMENT 20020507

17Q First examination report despatched

Effective date: 20030704

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WARNER-LAMBERT COMPANY LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040115